Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $20.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1629030242?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.0006/04/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833593479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $13.05 12/31/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914594193
Principal investigator 1 Merck Sharp & Dohme LLC $384.43 12/31/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine, administered in Preadolescents and Adolescents 9 to 14 year olds with a Comparison to Young Women 16 to 26 year olds No dispute reported 06/30/2026 940394777
Principal investigator 1 Merck Sharp & Dohme LLC $126.49 12/31/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 940396013
Principal investigator 1 Merck Sharp & Dohme LLC $27,832.90 12/31/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400859
Principal investigator 1 Merck Sharp & Dohme LLC $575.60 12/31/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400861
Principal investigator 1 Merck Sharp & Dohme LLC $1,407.06 12/31/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400863
Recipient ModernaTX, Inc. $23,909.88 12/23/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548029
Principal investigator 1 PFIZER INC. $6,877.44 12/21/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949774655
Principal investigator 1 PFIZER INC. $8,092.50 12/21/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 949774839
Principal investigator 1 PFIZER INC. $3,849.30 12/21/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949774855
Principal investigator 1 PFIZER INC. $2,138.50 12/17/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949774653
Principal investigator 1 PFIZER INC. $2,002.00 12/16/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949774859
Principal investigator 1 PFIZER INC. $11,527.10 12/14/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 949774439
Principal investigator 1 PFIZER INC. $16,047.36 12/14/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949774885
Principal investigator 1 Merck Sharp & Dohme LLC $140,391.60 12/12/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940400857
Principal investigator 1 PFIZER INC. $64,064.00 12/10/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949774817
Principal investigator 1 PFIZER INC. $1,462.02 12/09/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949774841
Principal investigator 1 GlaxoSmithKline, LLC. $418.30 12/07/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 965505811
Principal investigator 1 PFIZER INC. $12,507.30 12/07/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 949774441
Principal investigator 1 PFIZER INC. $5,731.20 12/07/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949774857
Principal investigator 1 PFIZER INC. $5,164.06 12/07/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949774887
Recipient ModernaTX, Inc. $78,540.25 12/01/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548027
Principal investigator 1 PFIZER INC. $10,000.00 11/30/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 949779231
Principal investigator 1 PFIZER INC. $4,584.96 11/30/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949779457
Principal investigator 1 PFIZER INC. $7,257.60 11/29/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949779421
Principal investigator 1 PFIZER INC. $10,550.00 11/23/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949779791
Principal investigator 1 PFIZER INC. $37.26 11/21/2022 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949761379
Principal investigator 1 PFIZER INC. $731.01 11/16/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949779419
Principal investigator 1 PFIZER INC. $48,576.88 11/15/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949779793
Principal investigator 1 GlaxoSmithKline, LLC. $3,882.59 11/11/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943975317
Principal investigator 1 PFIZER INC. $12,608.64 11/05/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949779763
Recipient ModernaTX, Inc. $3,025.52 11/02/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548015
Principal investigator 1 PFIZER INC. $18,339.84 10/29/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949788617
Principal investigator 1 PFIZER INC. $55.89 10/27/2022 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949761381
Principal investigator 1 PFIZER INC. $6,678.93 10/26/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949794303
Principal investigator 1 PFIZER INC. $141,504.90 10/19/2022 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949788615
Principal investigator 1 PFIZER INC. $3,655.05 10/06/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949794593
Recipient ModernaTX, Inc. $16,786.60 10/05/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963547989
Principal investigator 1 PFIZER INC. $68,192.68 10/01/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949794273
Principal investigator 1 PFIZER INC. $42,119.44 10/01/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949794275
Principal investigator 1 PFIZER INC. $4,059.37 09/28/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949792901
Principal investigator 1 PFIZER INC. $177,196.62 09/22/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949794619
Principal investigator 1 PFIZER INC. $12,227.00 09/10/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949792969
Recipient ModernaTX, Inc. $114,636.92 09/07/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963547969
Principal investigator 1 GlaxoSmithKline, LLC. $11,930.44 09/05/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943975321
Principal investigator 1 SANOFI PASTEUR INC. $3,339.00 08/26/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562973
Principal investigator 1 PFIZER INC. $192.00 08/24/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949802559
Principal investigator 1 PFIZER INC. $320.00 08/24/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949803799
Principal investigator 1 PFIZER INC. $20,785.72 08/23/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949802841
Principal investigator 1 PFIZER INC. $3,624.96 08/23/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949804109
Principal investigator 1 PFIZER INC. $3,128.58 08/17/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949801549
Principal investigator 1 PFIZER INC. $25,260.03 08/17/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949802523
Principal investigator 1 PFIZER INC. $20,796.22 08/17/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949804345
Principal investigator 1 GlaxoSmithKline, LLC. $18,627.30 08/12/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943975319
Recipient ModernaTX, Inc. $6,477.68 08/10/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963547901
Principal investigator 1 PFIZER INC. $7,147.53 08/10/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949803995
Principal investigator 1 PFIZER INC. $49,980.15 08/04/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949800913
Principal investigator 1 PFIZER INC. $65,221.95 08/04/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949801317
Principal investigator 1 PFIZER INC. $2,416.64 08/04/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949803745
Principal investigator 1 PFIZER INC. $3,268.58 08/03/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949801965
Principal investigator 1 PFIZER INC. $30,213.79 08/02/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949804085
Principal investigator 1 PFIZER INC. $5,293.79 07/28/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949810051
Principal investigator 1 PFIZER INC. $1,208.32 07/21/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949810049
Principal investigator 1 PFIZER INC. $33,606.50 07/20/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949810107
Principal investigator 1 SANOFI PASTEUR INC. $2,681.00 07/15/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562967
Principal investigator 1 PFIZER INC. $37,676.50 07/13/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949809901
Principal investigator 1 PFIZER INC. $1,812.48 07/08/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949809487
Principal investigator 1 GlaxoSmithKline, LLC. $9,924.96 07/06/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943975325
Principal investigator 1 PFIZER INC. $67,112.20 07/06/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949809485
Principal investigator 1 PFIZER INC. $320.00 07/06/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949810105
Principal investigator 1 PFIZER INC. $301,901.22 07/01/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949809903
Principal investigator 1 PFIZER INC. $29,371.97 06/30/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949811389
Principal investigator 1 PFIZER INC. $76,881.16 06/30/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949812447
Principal investigator 1 AstraZeneca UK Limited $270.00 06/24/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914591369
Principal investigator 1 PFIZER INC. $4,833.28 06/21/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949812445
Principal investigator 1 SANOFI PASTEUR INC. $3,823.00 06/17/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562955
Principal investigator 1 GlaxoSmithKline, LLC. $52,086.62 06/10/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943975323
Principal investigator 1 PFIZER INC. $1,021.44 06/08/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949812075
Principal investigator 1 PFIZER INC. $2,256.39 06/03/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949811391
Principal investigator 1 PFIZER INC. $281.25 06/03/2022 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949812311
Principal investigator 1 PFIZER INC. $3,020.80 06/02/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949811393
Principal investigator 1 PFIZER INC. $1,773.44 06/01/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949812313
Recipient ModernaTX, Inc. $20,760.17 05/25/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963547905
Principal investigator 1 PFIZER INC. $4,303.36 05/25/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949753099
Principal investigator 1 PFIZER INC. $9,805.74 05/25/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949753993
Principal investigator 1 PFIZER INC. $1,329.92 05/21/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949753095
Principal investigator 1 PFIZER INC. $4,966.92 05/21/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949753547
Principal investigator 1 PFIZER INC. $20,557.06 05/20/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949753745
Principal investigator 1 SANOFI PASTEUR INC. $1,142.00 05/20/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562949
Principal investigator 1 GlaxoSmithKline, LLC. $6,947.93 05/13/2022 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943975327
Principal investigator 1 PFIZER INC. $4,966.92 05/06/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949753541
Principal investigator 1 PFIZER INC. $1,208.32 05/05/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949753987
Recipient ModernaTX, Inc. $31,504.23 05/04/2022 Covered Recipient Physician A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963547907
Principal investigator 1 PFIZER INC. $6,075.06 05/03/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949753997
Principal investigator 1 PFIZER INC. $287,697.12 04/30/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949819117
Principal investigator 1 PFIZER INC. $360.45 04/22/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949819641
Principal investigator 1 SANOFI PASTEUR INC. $5,275.00 04/22/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562943
Principal investigator 1 PFIZER INC. $4,958.72 04/21/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949818945
Principal investigator 1 PFIZER INC. $6,785.72 04/20/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949818865
Principal investigator 1 PFIZER INC. $11,992.44 04/19/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949819119
Principal investigator 1 PFIZER INC. $639.48 04/13/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949819643
Principal investigator 1 PFIZER INC. $5,684.48 04/07/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949819003
Principal investigator 1 PFIZER INC. $639.48 04/06/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949819719
Principal investigator 1 PFIZER INC. $768.00 04/01/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949819639
Principal investigator 1 PFIZER INC. $1,629.18 03/31/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949827793
Principal investigator 1 PFIZER INC. $639.48 03/30/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949827731
Principal investigator 1 PFIZER INC. $18,720.00 03/29/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949827761
Principal investigator 1 PFIZER INC. $675.07 03/29/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827819
Principal investigator 1 PFIZER INC. $562.50 03/23/2022 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949827915
Principal investigator 1 PFIZER INC. $9,381.90 03/22/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949827917
Principal investigator 1 PFIZER INC. $3,517.14 03/22/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827945
Principal investigator 1 PFIZER INC. $9,987.48 03/16/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949827791
Principal investigator 1 PFIZER INC. $109.40 03/10/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949810773
Principal investigator 1 PFIZER INC. $10,830.81 03/08/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827729
Principal investigator 1 PFIZER INC. $560.00 03/05/2022 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949811327
Principal investigator 1 PFIZER INC. $562.50 03/03/2022 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949827763
Principal investigator 1 PFIZER INC. $16,438.62 03/03/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949827765
Principal investigator 1 PFIZER INC. $5,620.08 03/03/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949827789
Principal investigator 1 PFIZER INC. $12,873.84 03/02/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949827817
Principal investigator 1 PFIZER INC. $6,772.50 03/02/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949827947
Principal investigator 1 PFIZER INC. $56,772.59 03/01/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827727
Principal investigator 1 PFIZER INC. $11,879.40 03/01/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949827949
Principal investigator 1 SANOFI PASTEUR INC. $855.00 02/25/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562927
Principal investigator 1 PFIZER INC. $230.00 02/23/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949811323
Principal investigator 1 PFIZER INC. $28.45 02/23/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949811383
Principal investigator 1 PFIZER INC. $79.00 02/23/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949811385
Principal investigator 1 PFIZER INC. $18,065.00 02/21/2022 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949758475
Principal investigator 1 PFIZER INC. $10,470.40 02/08/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949827519
Principal investigator 1 PFIZER INC. $4,701.69 02/04/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949826763
Principal investigator 1 PFIZER INC. $12,767.50 02/04/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949827523
Principal investigator 1 PFIZER INC. $201,452.80 02/01/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949826765
Principal investigator 1 PFIZER INC. $78,531.36 02/01/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827521
Principal investigator 1 PFIZER INC. $16,808.96 01/25/2022 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 949829157
Principal investigator 1 PFIZER INC. $73,784.28 01/25/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949829159
Principal investigator 1 PFIZER INC. $2,782.21 01/21/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949828405
Principal investigator 1 PFIZER INC. $9,625.10 01/20/2022 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949829225
Principal investigator 1 PFIZER INC. $2,208.27 01/08/2022 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949829155
Principal investigator 1 PFIZER INC. $693.75 01/07/2022 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949830871
Principal investigator 1 SANOFI PASTEUR INC. $1,710.00 01/07/2022 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935562903